A platform for research: civil engineering, architecture and urbanism
Sarcopenia and myosteatosis are associated with low survival in patients receiving lenvatinib for unresectable hepatocellular carcinoma
Sarcopenia and myosteatosis are associated with low survival in patients receiving lenvatinib for unresectable hepatocellular carcinoma
Sarcopenia and myosteatosis are associated with low survival in patients receiving lenvatinib for unresectable hepatocellular carcinoma
Journal of the Formosan Medical Association
Luo, Pei-Jui (author) / Chuang, Kai-I (author) / Ni, Cheng-Fu (author) / Yeh, Hsiao-Yu (author) / Wu, Ming-Shun (author) / Hsieh, Yao-Yu (author) / Kao, Wei-Yu (author) / Wu, Chih-Horng (author)
2025-01-01
Article (Journal)
Electronic Resource
English
Lactylation‐Driven HECTD2 Limits the Response of Hepatocellular Carcinoma to Lenvatinib
Wiley | 2025
|Hepatocellular carcinoma disguised as liver abscesses
British Library Online Contents | 2018
|Social network associated with depressed mood and sarcopenia among older adults in Taiwan
Elsevier | 2024
|